This is a working overview of c-Met receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-23. Anything still debated is marked as such rather than presented as settled.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
=== Cannabis === On May 31, 2019, the Illinois General Assembly passed the Illinois Cannabis Regulation and Tax Act legalizing and regulating the production, consumption, and sale of adult-use cannabis. On June 25, 2019, Pritzker signed the legislation into law, which went into effect on January 1, 2020. Illinois was the 11th U.S. state to legalize recreational use of cannabis. Criminal records of people caught possessing less than 30 grams were cleared. Tax revenue collected from cannabis sales is used to invest in impoverished communities affected by the war on drugs and in drug rehabilitation programs. After the first month of legalization, cannabis sales generated approximately $10.4 million in tax revenue. Cannabis sales were over $52 million by July 2020, $445.3 million by the end of 2022, and $2 billion by the end of 2024, which generated about $490 million in sales tax revenue. On December 31, 2019, Pritzker pardoned approximately 11,000 people for low-level cannabis convictions. In 2020, Pritzker pardoned an additional 9,200 people with low-level cannabis convictions and expunged the arrest records of 490,000 convictions related to cannabis.
=== Musical career === Pudzianowski often appears as a guest singer in the musical group Pudzian Band, formed by his brother Krystian. Their first single Zdobyć świat (To conquer the world), was released in 2006. In 2009, the group released an album, Dawaj na ring (Go, hit the ring).
== Malignant neoplasm of respiratory and intrathoracic organs (160–165) == 160 Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses 161 Malignant neoplasm of larynx 162 Malignant neoplasm of trachea, bronchus, and lung 162.0 Trachea 162.2 Main bronchus 162.3 Upper lobe, bronchus or lung 162.4 Middle lobe, bronchus or lung 162.5 Lower lobe, bronchus or lung 162.8 Other parts of bronchus or lung 162.9 Bronchus and lung, unspecified 163 Malignant neoplasm of pleura 164 Malignant neoplasm of thymus, heart, and mediastinum 165 Malignant neoplasm of other and ill-defined sites within the respiratory system and intrathoracic organs
In a chemical reaction, chemical equilibrium is the state in which both the reactants and products are present in concentrations which have no further tendency to change with time, so that there is no observable change in the properties of the system. This state results when the forward reaction proceeds at the same rate as the reverse reaction. The reaction rates of the forward and backward reactions are generally not zero, but they are equal. Thus, there are no net changes in the concentrations of the reactants and products. Such a state is known as dynamic equilibrium. It is the subject of study of equilibrium chemistry.
The recommended daily intakes for children aged three years and older is 10% to 20% higher than adult levels and those for infants can be as much as 150% higher in the first year of life. Cysteine (or sulfur-containing amino acids), tyrosine (or aromatic amino acids), and arginine are always required by infants and growing children. Methionine and cysteine are grouped together because one of them can be synthesized from the other using the enzyme methionine S-methyltransferase and the catalyst methionine synthase. Phenylalanine and tyrosine are grouped together because tyrosine can be synthesized from phenylalanine using the enzyme phenylalanine hydroxylase.
Sources: en.wikipedia.org
Guest speakers that term included Rajani Palme Dutt, Lady Violet Bonham Carter, his old headmaster John Wolfenden and Jacob Bronowski, whilst Aneurin Bevan addressed a packed meeting of the University Labour Club, chaired by Anthony Howard, in the Union Chamber.
== Science and technology == Process capability index (Cpk), a measure of process capability CPK coloring, a way to color atoms when visualizing molecular models Creatine phosphokinase, an enzyme found in humans, or alternatively a blood test for it
He remained director of the NIH facility until the NIH no longer funded such facilities and retired from his teaching position in 2006. The MS Facility continued to operate after funding stopped through the efforts of Watson, the Biochemistry and Chemistry Departments.
Half-Life was followed by an expansion pack, Opposing Force, on November 1, 1999, developed by Gearbox Software. Players control US Marine corporal Adrian Shephard, who fights a new group of aliens and black operations units. Opposing Force was received favorably by critics, many citing the game as being as influential on setting expansion pack standards as the original game had been in influencing the overall genre. The game won the Computer Game of the Year Interactive Achievement Award of 2000 from the Academy of Interactive Arts & Sciences.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.